• Je něco špatně v tomto záznamu ?

Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial

S. Pignata, A. Oza, G. Hall, B. Pardo, R. Madry, D. Cibula, J. Klat, A. Montes, R. Glasspool, N. Colombo, I. Pete, A. Herrero Ibáñez, MR. Marín, R. Ilieva, C. Timcheva, M. Di Maio, C. Blakeley, R. Taylor, A. Barnicle, A. Clamp

. 2023 ; 172 (-) : 121-129. [pub] 20230406

Jazyk angličtina Země Spojené státy americké

Typ dokumentu multicentrická studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011550

BACKGROUND: The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. METHODS: Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. RESULTS: 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3 months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3-22.1), 16.6 (12.4-22.2), 19.3 (14.3-27.6) and 16.4 (10.9-19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. CONCLUSIONS: Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011550
003      
CZ-PrNML
005      
20230801133129.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ygyno.2023.03.019 $2 doi
035    __
$a (PubMed)37030280
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pignata, Sandro $u Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy. Electronic address: s.pignata@istitutotumori.na.it
245    10
$a Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial / $c S. Pignata, A. Oza, G. Hall, B. Pardo, R. Madry, D. Cibula, J. Klat, A. Montes, R. Glasspool, N. Colombo, I. Pete, A. Herrero Ibáñez, MR. Marín, R. Ilieva, C. Timcheva, M. Di Maio, C. Blakeley, R. Taylor, A. Barnicle, A. Clamp
520    9_
$a BACKGROUND: The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. METHODS: Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. RESULTS: 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3 months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3-22.1), 16.6 (12.4-22.2), 19.3 (14.3-27.6) and 16.4 (10.9-19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. CONCLUSIONS: Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    12
$a nádory vaječníků $x farmakoterapie $x genetika $x patologie $7 D010051
650    _2
$a kvalita života $7 D011788
650    _2
$a rekombinační oprava DNA $7 D059767
650    _2
$a prospektivní studie $7 D011446
650    _2
$a epiteliální ovariální karcinom $x farmakoterapie $x genetika $7 D000077216
650    _2
$a ftalaziny $x škodlivé účinky $7 D010793
650    _2
$a mutace $7 D009154
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x genetika $7 D009364
650    _2
$a zárodečné mutace $7 D018095
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Oza, Amit $u Princess Margaret Cancer Centre, Toronto, Ontario, Canada
700    1_
$a Hall, Geoff $u St James's University Hospital, Leeds, UK
700    1_
$a Pardo, Beatriz $u ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
700    1_
$a Madry, Radoslaw $u Medical University Karol Marcinkowski, Poznań, Poland
700    1_
$a Cibula, David $u General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Klat, Jaroslav $u University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Montes, Ana $u Guy's and St Thomas' NHS Foundation Trust, London, UK
700    1_
$a Glasspool, Rosalind $u Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK
700    1_
$a Colombo, Nicoletta $u University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Pete, Imre $u National Institute of Cancer, Budapest, Hungary
700    1_
$a Herrero Ibáñez, Ana $u Hospital Universitario Miguel Servet, Zaragoza, Spain
700    1_
$a Marín, Margarita Romeo $u ICO Badalona - Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
700    1_
$a Ilieva, Rumyana $u MHAT 'Central Onco Hospital', OOD, Plovdiv, Bulgaria
700    1_
$a Timcheva, Constanta $u MHAT for Women's Health - Nadezhda, OOD, Sofia, Bulgaria
700    1_
$a Di Maio, Massimo $u Department of Oncology, University of Turin, At Mauriziano Hospital, Turin, Italy
700    1_
$a Blakeley, Christopher $u AstraZeneca, Cambridge, UK
700    1_
$a Taylor, Rosie $u AstraZeneca, Cambridge, UK
700    1_
$a Barnicle, Alan $u AstraZeneca, Cambridge, UK
700    1_
$a Clamp, Andrew $u The Christie NHS Foundation Trust and University of Manchester, Manchester, UK
773    0_
$w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 172, č. - (2023), s. 121-129
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37030280 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133126 $b ABA008
999    __
$a ok $b bmc $g 1963772 $s 1197815
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 172 $c - $d 121-129 $e 20230406 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
LZP    __
$a Pubmed-20230718
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace